BACKGROUND: Circulating tumor cells (CTC) predict overall survival in patients with metastatic prostate cancer. The objective of this study is to measure CTC before radical prostatectomy in intermediate- and high-risk prostate cancer patients. MATERIALS AND METHODS: The study accrued 12 patients and 10 provided adequate peripheral blood sample. Blood was drawn preoperatively and assayed for CTC using the CellSearch system. Patients were categorized as CTC positive (≥ 1 CTC) or CTC negative (no CTC). RESULTS: Median age was 64.5 years (range 49-77 years), median prostate specific antigen was 7.4 ng/ml (range 5.7-25.7 ng/ml). Seven patients had intermediate-risk and 3 patients had high-risk prostate cancer. One patient was found to be CTC positive. CONCLUSIONS: Our pilot study shows that CTC are rare in patients with clinically localized disease despite intermediate- to high-risk features. CTC may not be the optimal marker to predict prognosis or detect residual disease after radical prostatectomy.
BACKGROUND: Circulating tumor cells (CTC) predict overall survival in patients with metastatic prostate cancer. The objective of this study is to measure CTC before radical prostatectomy in intermediate- and high-risk prostate cancerpatients. MATERIALS AND METHODS: The study accrued 12 patients and 10 provided adequate peripheral blood sample. Blood was drawn preoperatively and assayed for CTC using the CellSearch system. Patients were categorized as CTC positive (≥ 1 CTC) or CTC negative (no CTC). RESULTS: Median age was 64.5 years (range 49-77 years), median prostate specific antigen was 7.4 ng/ml (range 5.7-25.7 ng/ml). Seven patients had intermediate-risk and 3 patients had high-risk prostate cancer. One patient was found to be CTC positive. CONCLUSIONS: Our pilot study shows that CTC are rare in patients with clinically localized disease despite intermediate- to high-risk features. CTC may not be the optimal marker to predict prognosis or detect residual disease after radical prostatectomy.
Authors: Shannon L Stott; Richard J Lee; Sunitha Nagrath; Min Yu; David T Miyamoto; Lindsey Ulkus; Elizabeth J Inserra; Matthew Ulman; Simeon Springer; Zev Nakamura; Alessandra L Moore; Dina I Tsukrov; Maria E Kempner; Douglas M Dahl; Chin-Lee Wu; A John Iafrate; Matthew R Smith; Ronald G Tompkins; Lecia V Sequist; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran Journal: Sci Transl Med Date: 2010-03-31 Impact factor: 17.956
Authors: R Beach; A M Gown; M N De Peralta-Venturina; A L Folpe; H Yaziji; P G Salles; D J Grignon; G R Fanger; M B Amin Journal: Am J Surg Pathol Date: 2002-12 Impact factor: 6.394
Authors: William J Ellis; Jesco Pfitzenmaier; Janet Colli; Edward Arfman; Paul H Lange; Robert L Vessella Journal: Urology Date: 2003-02 Impact factor: 2.649
Authors: Howard I Scher; Xiaoyu Jia; Johann S de Bono; Martin Fleisher; Kenneth J Pienta; Derek Raghavan; Glenn Heller Journal: Lancet Oncol Date: 2009-02-11 Impact factor: 41.316
Authors: John W Davis; Hiroyuki Nakanishi; Vikas S Kumar; Viju A Bhadkamkar; Robert McCormack; Herbert A Fritsche; Beverly Handy; Terrie Gornet; R Joseph Babaian Journal: J Urol Date: 2008-04-18 Impact factor: 7.450
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Jussuf T Kaifi; Guangfu Li; Gary Clawson; Eric T Kimchi; Kevin F Staveley-O'Carroll Journal: Cancer Biol Ther Date: 2016-04-05 Impact factor: 4.742
Authors: Ignacio Puche-Sanz; María J Alvarez-Cubero; Manrique Pascual-Geler; Alba Rodríguez-Martínez; Miguel Delgado-Rodríguez; José L García-Puche; José Expósito; Inmaculada Robles-Fernández; Carmen Entrala-Bernal; José A Lorente; José M Cózar-Olmo; María J Serrano Journal: Oncotarget Date: 2017-07-31